Tirzepatide improves glycemic control and weight loss in patients with type 2 diabetes
1. Tirzepatide was superior to placebo with regard to changes in HbA1c, serum glucose, body weight loss, and proportion of ...
1. Tirzepatide was superior to placebo with regard to changes in HbA1c, serum glucose, body weight loss, and proportion of ...
1. Time spent cycling was associated with lower all-cause and cardiovascular disease-specific mortality in this multicenter European cohort study of ...
1. In patients with type 2 diabetes, use of sodium-glucose cotransporter 2 inhibitors was associated with reduced risk of all-cause ...
1. Widespread diabetes screening helps to identify asymptomatic patients with preserved renal function and low diabetes-associated cardiovascular risk. 2. New ...
1. Matched cohort meta-analysis showed significant morality and life expectancy benefits with metabolic–bariatric surgery compared to non-surgical management of obesity. ...
1. Semaglutide 2.4 mg combined with once weekly cagrilintide therapy was not associated with increase in adverse events compared to ...
1. Hospital readmission and mortality rates were higher in post-COVID patients as compared to matched control groups. 2. More diagnoses ...
1. Change in mean bodyweight was -9.6% with semaglutide 2.4 mg vs. -3.4% with placebo. 2. Approximately two-thirds of patients ...
1. Compared to patients of European descent, poorer health outcomes were seen among Māori and Pacific New Zealanders with type ...
1. 10-year remission rates were significantly higher for Roux-en-Y gastric bypass (RYGB) and biliopancreatic diversion (BPD) than medical therapy. 2. ...
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.